| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH) |
| 掲載誌名 | 正式名：Journal of clinical oncology 略 称：J Clin Oncol ISSNコード：0732183X/15277755 |
| 巻・号・頁 | 35(24),pp.2781-2789 |
| 著者・共著者 | Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. |
| 発行年月 | 2017/08 |
| DOI | 10.1200/JCO.2016.71.9476 |
| 文献番号 | 28609226 |
| PMID | 28609226 |